Halozyme Therapeutics : Corporate Presentation

Corporate Presentation

Nasdaq: HALO

November 2022

Forward-Looking Statements

In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance (including the Company's financial outlook for 2022) and expectations for profitability, revenue (including expectations for future milestones and royalties), operating income, and earnings-per-share, and the Company's plans to repurchase shares under its share repurchase program and to potentially expand the Company's platform through acquisitions. Forward-looking statements regarding the Company's ENHANZE® drug delivery

technology may include the possible benefits and attributes of ENHANZE® including its potential application to aid in the dispersion and absorption of other injected

therapeutic drugs and facilitating more rapid delivery and administration of larger volumes of injectable medications through subcutaneous delivery. Forward-looking statements may also include potential growth driven by our and our partners' development and commercialization efforts (including anticipated new clinical trial starts, pipeline advancements, product approvals and commercial launches), projections for future sales revenue of our partners' products, potential new ENHANZE® and other collaborations, collaborative targets and indications for ENHANZE® products, co-formulation intellectual property and the Company's plans to develop a large volume autoinjector and new formulations of its API for longer intellectual property protection. These forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning and involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including unexpected levels of revenues

(including royalty and milestone revenue received from our collaboration partners), expenditures and costs, unexpected delays in the execution of the Company's share

repurchase program, unexpected results or delays in the growth of the Company's ENHANZE® business, obtaining new co-formulation intellectual property, or in the development, regulatory review or commercialization of new formulations of the Company's API or its proprietary or partnered products, including any potential delays caused by the current COVID-19 global pandemic, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Non-GAAP Financial Measures:

In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), these materials contain certain non-

GAAP financial measures. The Company reports non-GAAP net income and non-GAAP diluted earnings per share, and guidance with respect to those measures, and expectations of those measures in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The Company uses Non- GAAP financial information in assessing what it believes is a meaningful and comparable set of financial performance measures to evaluate operating trends, as well as in establishing portions of our performance-based incentive compensation programs. Reconciliations between GAAP and non-GAAP financial measures are included in these materials.

Note: This presentation contains product names, trademarks and registered trademarks are property of their respective owners.

Halozyme Confidential and Proprietary	2

Halozyme Company Overview

The ENHANZE® Drug Delivery Platform combined with innovative autoinjector device technology

provides unique therapeutic solutions for partners, patients and health care providers

Investment Highlights

Profitable biopharma company with diversified revenue streams

Commercially validated portfolio with proprietary and partner products

Licensable differentiated auto injector device platforms can drive meaningful revenue opportunities

Investment to maximize revenue growth and durability

2022 revenue guidance of $655-685 million (+48-55% increase from 2021 revenue of $443.3 million)

Halozyme Confidential and Proprietary	3

Strategic Growth and Capital Allocation Priorities

Leverage drug delivery technology

ENHANZE® and auto-injector

Grow commercial revenue

Continue to return capital to shareholders

Identify opportunities for external growth

Halozyme Confidential and Proprietary	4

ENHANZE® Technology

Patented, Commercially Validated Platform Enabling Subcutaneous Delivery of IV Drugs

IV Drug Delivery

ENHANZE® Technology

With Subcutaneous Delivery

syringe needle

Time-consuming administration	Halozyme's fully owned rHuPH20 enzyme	Temporarily degrades extracellular matrix
		enabling increased fluid flow and
		dispersion of drugs co-formulated
		with ENHANZE®

>600,000 Patients Treated With Commercial Products Incorporating ENHANZE®

Halozyme Confidential and Proprietary	5